ImmunityBio (NASDAQ:IBRX) closed at $5.52, up 39.75% due to Anktiva revenue growth, positive oncology trial data, and new approvals. Trading volume surged to 176 million shares, surpassing its three-month average by 1,254%. The stock has fallen 85% since its 2015 IPO.

S&P 500 (SNPINDEX:^GSPC) slipped 0.06% while Nasdaq Composite (NASDAQINDEX:^IXIC) eased 0.06%. Iovance Biotherapeutics (NASDAQ:IOVA) and Krystal Biotech (NASDAQ:KRYS) rose 6.31% and 1.07% respectively. Iovance Biotherapeutics closed at $2.36, up 6.31%, and Krystal Biotech ended at $285.04, gaining 1.07%.

ImmunityBio’s Anktiva preliminary 2025 net product revenue reached $113 million, showing 700% YoY growth and 431% for the quarter. Positive news about its bladder cancer drug trial reinforced expectations. Short interest fueled the stock’s 40% increase, but the news was positive overall.

Missed out on successful stocks? Our analysts issue “Double Down” stock recommendations for upcoming opportunities. Nvidia, Apple, and Netflix have seen substantial returns for investors who got in early. Don’t miss out on the next big investment opportunity.

Read more at Yahoo Finance: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year